GLP-1, Fc-Fusion Recombinant (GLP-1 Agonist)

Only %1 left

Catalog #

102006

As low as $305 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant human GLP-1 (glucagon-like peptide 1), encompassing amino acids 7-37. This construct contains a C-terminal Fc-Tag from human IgG4, and includes 3 mutations of interest: A8G, G22E and R36G. This protein was affinity purified.

●

Synonyms

GLP-1 receptor, GLP-1-R, GLP-1R, Glucagon-like peptide 1 receptor

●

Product Data Gallery

4-20% SDS-PAGE Coomassie Staining

GLP-1/CRE Activity

Product Info

Storage and Usage

Citations

Species

Human

Construct

GLP-1 (7-37-Fc(IgG4))

Mutation

A8G, G22E, and R36G

Host Species/Expression System

HEK293

Purity

≥90%

Format

Aqueous buffer solution.

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

30 kDa

Amino Acids

7-37

UniProt #

P43220

Tag(s)

C-terminal Fc-Tag

Background

GLP-1R, a member of the class B family of G protein-coupled receptors (GPCRs or secretin-like receptors), is a transmembrane protein primarily found in pancreatic β cells and brain neurons and is activated by the peptide hormone glucagon-like peptide 1 (GLP-1) and glucagon that is secreted from intestinal L-cells after nutrient ingestion. GLP-1R plays an important role in controlling blood sugar level by enhancing glucose-stimulated insulin secretion, glucose, lipid metabolism, and satiety. Its role in the brain seems to be in the control of appetite. Research efforts have focused on the regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to type 2 diabetes (T2DM) and have resulted in the development of several FDA-approved GLP-1R agonists. Dulaglutide, with the brand name of Trulicity, is a GLP-1R agonist, approved for commercialization since 2014, and by 2020 was amongst the most sold medications in the United States. It is used for the treatment of type 2 diabetes and associated cardiovascular complications. A role in tumor development in patients with T2DM is also being investigated but further studies are required to fully understand the functions of GLP-1R and its agonists.

Storage/Stability

At least 6 months at -80°C.

Assay Conditions

GLP-1R/CRE Luciferase Reporter HEK293 cells (BPS Bioscience #78176) were plated according to the cell line protocol. A serial dilution of GLP-1 Agonist was prepared and added to the cells. The cells were incubated at 37°C and 5% CO2 for 5-6 hours. Luciferase activity was measured using the One-Step™ Luciferase Assay System (BPS Bioscience #60690). Data is shown as fold induction of CRE luciferase reporter expression versus an unstimulated control.

Instructions for Use

Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.

Applications

Useful as an agonist to GLP-1R.

Shipping Temperature

-80°C

Warnings

Avoid freeze/thaw cycles

Scientific Category

Diabetes and Obesity

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

●

Datasheets/Protocols

102006 lot 231220

Datasheets provide example lot-specific information. Contact us to request information on currently available lots.

● General Protocols

● FAQs

● Contact Technical Service

●

GLP-1, Fc-Fusion Recombinant (GLP-1 Agonist)

PRODUCTS

SERVICES

RESOURCES

COMPANY